Efficiency and tolerance of acne therapy using system isotretinoin

Cover Page


Purpose. Determination of efficiency and tolerance of Sotret product in treatment of patients with different clinical forms and severe acne in three clinical investigations. Materials and methods. 103 patients with acne (moderate and severe acne, acne conglobata and acne inversa) were examined and treated. All patients underwent monotherapy with Sotret with clinical effectiveness assessment and records of adverse events. Results. Sotret therapy facilitated clinical remission of acne in 90-100% of cases. Adverse events were easily tolerated and were not serious. Conclusion. Established therapeutic efficiency of Sotret determines its potential in treating various severity and various forms of acne.

  1. Zouboulis C.C., Katsambas A.D., Kligman A.M. Pathogenesis and treatment of acne and rosacea. Springer Heidelberg New York Dordrecht London 2014, 53.
  2. Cordain L., Linderberg S., Hurtado M. et al. Acne vulgaris: a desease of Western civilization. Arch Dermatol 2002; 119: 1317-1322.
  3. Shalita A.R. Acne: clinical presentations. Clin Dermatol 2004; 22: 385-386.
  4. Dreno B., Poli F. Epidemiology of acne. 20-th World Congress Dermatology. Ann Dermatol Venerol 2002; 132.
  5. Kungurov N.V., Kokhan M.M., Zil'berberg N.V. i dr. Terapiya bol'nykh akne i postakne. Metodicheskie rekomendatsii. Ekaterinburg, 2013; 6. [кунгуров Н.В., кохан М.М., Зильберберг Н.В. и др. Терапия больных акне и постакне. Методические рекомендации. Екатеринбург, 2013; 6.]
  6. Lee M.R. Cooper A. Acne vulgaris in monozygotic twins. Australas J Dermatol 2006; 47: 145.
  7. Thiboutot D., Gollnick H., Bettoli V. et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60: 1-50.
  8. Zouboulis C.C. Acne as a chronic systemic disease. Clin Dermatol 2014; 32: 389-396.
  9. Statsenko A.V., Belousova I.E., Khayrutdinov V.R. et al. Clinical experience of administering isotretinoin in therapy of severe acne. Effective Pharmacotherapy 2014; (4): 3-5. [Стаценко А.В., Белоусова И.Э., Хайрутдинов В.Р. и др. клинический опыт применения изотретиноина в терапии тяжелых форм акне. Эффективная фармакотерапия 2014; (4): 3-5.]
  10. Gollnick H. Current concept of the pathogenesis of acne: implication for drug treatment. Drugs 2003; 63: 1579-1596.
  11. Samgin M.A., Monakhov S.A. Sovremennyy vzglyad na vospalenie pri akne. Vestn dermatol venerol 2003; (6): 48-49. [Самгин М.А., Монахов С.А. Современный взгляд на воспаление при акне. Вестн дерматол венерол 2003; (6): 48-49.]
  12. Cunliffe W.J. Acne: when, where and how to treat. Practitioner 2000;. 244; 865-866, 868, 870-871.
  13. Perlamutrov Yu.N., Ol'khovskaya K.B. Sovremennye aspekty effektivnoy terapii acne vulgaris. Russ J Skin Venereal Dis 2014; (5): 51-54. [Перламутров Ю.Н., Ольховская к.Б. Современные аспекты эффективной терапии acne vulgaris. Росс журн кожн вен бол 2014; (5): 51-54.]
  14. Wolverton S.E., Harper J.C. Important controversies associated with isotretinoin therapy for acne. Am J Clin Dermatol 2013; 14: 71-76.
  15. Nast A., Dréno B., Bettoli V. et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 1: 1-29.
  16. Kokhan M.M., Keniksfest Iu.V., Shaibakova lu.B. et al. Experience of treating patients with various forms of acne using systemic isotretinoin. Сііп Dermatol Venerol 2014; (2): 91-99. [кохан М.М., кениксфест Ю.В., Шайбакова Ю.Б. и др. Опыт терапии больных различными формами акне препаратом системного изотретиноина. клин дерматол венерол 2014 (2); 91-99.]
  17. Layton A.M., Dreno B., Gollnick H.P. et al. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 773-776.
  18. Goodfield M.J., Cox N.H., Bowser A. et al. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010. Br J Dermatol 2010; 162: 1172-1179.


Abstract - 85

PDF (Russian) - 20


  • There are currently no refbacks.

Copyright (c)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies